Actively Recruiting
Safety and Effectiveness Study of REGN5668 Alone or With Cemiplimab, Cemiplimab Plus Fianlimab, or Ubamatamab in Women With MUC16-Positive Ovarian and Uterine Cancers
Led by Regeneron Pharmaceuticals · Updated on 2026-09-24
612
Participants Needed
28
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an investigational drug called REGN5668 alone or combined with cemiplimab, cemiplimab plus fianlimab, or ubamatamab, with or without sarilumab, in adult women with ovarian or uterine cancers. The study aims to find the highest safe dose of these combinations and to learn about their safety and potential to treat these cancers. It includes two parts Part 1 focuses on dose escalation to determine safe dosing, and Part 2 uses those doses to further evaluate treatment effects, including women with uterine cancer who participate only in Part 2. Participants receive REGN5668 alone or in combination with cemiplimab, cemiplimab plus fianlimab, or ubamatamab following the protocol. The study evaluates multiple treatment combinations sequentially, observing side effects and how the drugs work in the body. The study drugs are administered according to the studys schedule, and dosing adjustments may occur based on safety findings in Part 1, with Part 2 using selected doses for further evaluation. Throughout participation, researchers monitor safety by tracking dose-limiting toxicities, adverse events, laboratory abnormalities, and deaths over up to five years. They measure drug concentrations in the blood and assess treatment response using RECIST criteria. Participants will undergo assessments such as blood tests and imaging to evaluate cancer response and side effects. The total study duration can last up to five years, including long-term safety follow-up and monitoring of treatment effects.
CONDITIONS
Brief Title
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here